BFLY — Butterfly Network Inc. | August 27, 2025.Butterfly Network, Inc.BATS:BFLYSergioRichiBFLY #BFLY — Butterfly Network Inc. (NYSE:BFLY) | Healthcare | Medical Devices | USA | NYSE | August 27, 2025. Executive Summary Butterfly Network Inc. (NYSE: BFLY), an innovative medical device company specializing in portable ultrasound technology, exhibits strong insider conviction through a recent purchase by Chief Business Officer Steve Cashman. On August 25, 2025, Cashman acquired 50,000 shares of Class A common stock at an average price of $1.64 per share, totaling $81,953 in value. This transaction, disclosed via SEC Form 4 on August 27, 2025, increased his direct holdings to 2,324,474 shares, representing a significant vote of confidence in the company's trajectory amid a challenging market environment. Technical indicators on the daily chart suggest a potential reversal from a prolonged downtrend, with the stock trading at oversold levels and showing early signs of stabilization near $1.57. Q2 2025 financials reported record revenue of $23.4 million (up 9% YoY), with net losses narrowing by 59%, bolstered by cost efficiencies and AI-driven product enhancements. Recent news highlights include a new distribution agreement with Clipper Distributing for veterinary applications (August 25, 2025) and participation in an AI-assisted POCUS research project for tuberculosis detection in Sub-Saharan Africa (August 19, 2025), underscoring growth in both human and animal health sectors. Replicating Cashman's buy at approximately $1.64 presents a high probability of profitability, with estimated upside potential of 50-200% over the next 6-12 months, targeting $2.50-$5.00. This is supported by Zacks Rank #2 (Buy) and analyst projections of 124-127% upside. We recommend a speculative long position with tight risk controls, allocating 1-2% of portfolio capital, given the asymmetric reward in the medtech space. Company Profile Butterfly Network Inc. (BFLY) is a Burlington, Massachusetts-based healthcare technology firm revolutionizing medical imaging through its handheld, AI-enabled ultrasound devices. The flagship product, the Butterfly iQ+ probe, integrates semiconductor technology with cloud-based software to provide affordable, portable point-of-care ultrasound (POCUS) solutions for clinicians worldwide. The company operates in the medical devices sector, targeting applications in cardiology, emergency medicine, and now veterinary care, with a focus on democratizing access to diagnostic imaging in underserved markets. Key financial metrics as of August 27, 2025: • Market Capitalization: $395.24 million • Enterprise Value: $268.75 million (approx.) • Price-to-Sales (TTM): 4.52 • Price-to-Book (MRQ): 1.69 BFLY's business model emphasizes subscription-based software and AI integrations, with recent expansions into veterinary and global health initiatives driving revenue diversification. The company reported a cash position enabling continued R&D investment, though profitability remains elusive amid scaling efforts. Charts: • (1D) • (5D) Steve Cashman (Insider), Insider Trades: BFLY Ownership: SEC From 4: https://www.sec.gov/Archives/edgar/data/1804176/000106299325014953/xslF345X05/form4.xml Insider Activity Analysis Insider purchases, particularly by C-suite executives, often signal undervaluation and internal optimism about future catalysts. For BFLY, CBO Steve Cashman's August 25, 2025, acquisition of 50,000 shares at $1.64 per share is noteworthy, as it occurs near 52-week lows and follows a pattern of net insider buying. Post-transaction, Cashman's direct ownership stands at 2,324,474 shares, reflecting a substantial personal stake aligned with shareholders. Broader insider trends show mixed activity: While insiders sold approximately $1.6 million in stock over the past year, recent months have tilted toward buys, including this transaction. No other major executive purchases were reported in August 2025, but the absence of sales post-Q2 earnings suggests stabilizing sentiment. This aligns with historical data where clustered buys in medtech firms precede 20-50% rebounds within quarters, especially when tied to product launches or partnerships. Technical Analysis The daily chart for BFLY depicts a pronounced downtrend since peaking above $5.00 in early 2025, with the price eroding over 60% to current levels around $1.57 amid broader healthcare sector pressures. Price action forms a descending wedge pattern, characterized by lower highs and lows, trading below key simple moving averages (20-day SMA at $1.74, 50-day at $2.50, 200-day at $2.81), confirming bearish momentum. However, recent sessions exhibit green candles with modest volume spikes (e.g., 1.44M shares on August 27), hinting at accumulation. Key indicators bolster a high-probability reversal case: • Relative Strength Index (RSI, 14-period): At 49.65 on the primary chart (neutral) and 38.75 on the secondary (approaching oversold